Brokers Issue Forecasts for LLY FY2026 Earnings

Eli Lilly and Company (NYSE:LLY) – Investment analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Eli Lilly and Company in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst C. Gould expects that the company will post earnings of $32.40 per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $975.00 target price on the stock. The consensus estimate for Eli Lilly and Company’s current full-year earnings is $23.48 per share.

LLY has been the subject of a number of other reports. UBS Group decreased their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a report on Friday, May 2nd. Erste Group Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 5th. Hsbc Global Res cut shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research note on Monday, April 28th. The Goldman Sachs Group raised shares of Eli Lilly and Company from a “neutral” rating to a “buy” rating and reduced their price objective for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. Finally, Guggenheim reissued a “buy” rating on shares of Eli Lilly and Company in a research note on Friday, May 23rd. One analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,011.37.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $773.59 on Tuesday. The firm’s 50 day moving average is $769.95 and its two-hundred day moving average is $800.81. The firm has a market capitalization of $733.16 billion, a P/E ratio of 66.06, a PEG ratio of 1.40 and a beta of 0.40. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company’s revenue for the quarter was up 45.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.58 earnings per share.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors and hedge funds have recently modified their holdings of the stock. First Long Island Investors LLC boosted its position in shares of Eli Lilly and Company by 14.1% in the 1st quarter. First Long Island Investors LLC now owns 27,020 shares of the company’s stock valued at $22,316,000 after purchasing an additional 3,336 shares during the period. eCIO Inc. acquired a new stake in Eli Lilly and Company during the 1st quarter worth about $732,000. Harold Davidson & Associates Inc. raised its holdings in Eli Lilly and Company by 1.0% during the 1st quarter. Harold Davidson & Associates Inc. now owns 4,084 shares of the company’s stock worth $3,373,000 after buying an additional 42 shares during the period. CBIZ Investment Advisory Services LLC lifted its stake in Eli Lilly and Company by 14.2% during the first quarter. CBIZ Investment Advisory Services LLC now owns 548 shares of the company’s stock valued at $453,000 after buying an additional 68 shares in the last quarter. Finally, Jones Financial Companies Lllp lifted its stake in Eli Lilly and Company by 31.7% during the first quarter. Jones Financial Companies Lllp now owns 149,687 shares of the company’s stock valued at $123,177,000 after buying an additional 36,002 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares of the company’s stock, valued at $4,778,521.60. This trade represents a 14.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be issued a $1.50 dividend. The ex-dividend date is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.78%. Eli Lilly and Company’s payout ratio is currently 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.